FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100089051> ?p ?o ?g. }

• W2100089051 endingPage "1860" @default.
• W2100089051 startingPage "1849" @default.
• W2100089051 abstract "BackgroundLow-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention.MethodsWe undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascular death) and major bleeds in six primary prevention trials (95 000 individuals at low average risk, 660 000 person-years, 3554 serious vascular events) and 16 secondary prevention trials (17 000 individuals at high average risk, 43 000 person-years, 3306 serious vascular events) that compared long-term aspirin versus control. We report intention-to-treat analyses of first events during the scheduled treatment period.FindingsIn the primary prevention trials, aspirin allocation yielded a 12% proportional reduction in serious vascular events (0·51% aspirin vs 0·57% control per year, p=0·0001), due mainly to a reduction of about a fifth in non-fatal myocardial infarction (0·18% vs 0·23% per year, p<0·0001). The net effect on stroke was not significant (0·20% vs 0·21% per year, p=0·4: haemorrhagic stroke 0·04% vs 0·03%, p=0·05; other stroke 0·16% vs 0·18% per year, p=0·08). Vascular mortality did not differ significantly (0·19% vs 0·19% per year, p=0·7). Aspirin allocation increased major gastrointestinal and extracranial bleeds (0·10% vs 0·07% per year, p<0·0001), and the main risk factors for coronary disease were also risk factors for bleeding. In the secondary prevention trials, aspirin allocation yielded a greater absolute reduction in serious vascular events (6·7% vs 8·2% per year, p<0.0001), with a non-significant increase in haemorrhagic stroke but reductions of about a fifth in total stroke (2·08% vs 2·54% per year, p=0·002) and in coronary events (4·3% vs 5·3% per year, p<0·0001). In both primary and secondary prevention trials, the proportional reductions in the aggregate of all serious vascular events seemed similar for men and women.InterpretationIn primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds. Further trials are in progress.FundingUK Medical Research Council, British Heart Foundation, Cancer Research UK, and the European Community Biomed Programme. Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascular death) and major bleeds in six primary prevention trials (95 000 individuals at low average risk, 660 000 person-years, 3554 serious vascular events) and 16 secondary prevention trials (17 000 individuals at high average risk, 43 000 person-years, 3306 serious vascular events) that compared long-term aspirin versus control. We report intention-to-treat analyses of first events during the scheduled treatment period. In the primary prevention trials, aspirin allocation yielded a 12% proportional reduction in serious vascular events (0·51% aspirin vs 0·57% control per year, p=0·0001), due mainly to a reduction of about a fifth in non-fatal myocardial infarction (0·18% vs 0·23% per year, p<0·0001). The net effect on stroke was not significant (0·20% vs 0·21% per year, p=0·4: haemorrhagic stroke 0·04% vs 0·03%, p=0·05; other stroke 0·16% vs 0·18% per year, p=0·08). Vascular mortality did not differ significantly (0·19% vs 0·19% per year, p=0·7). Aspirin allocation increased major gastrointestinal and extracranial bleeds (0·10% vs 0·07% per year, p<0·0001), and the main risk factors for coronary disease were also risk factors for bleeding. In the secondary prevention trials, aspirin allocation yielded a greater absolute reduction in serious vascular events (6·7% vs 8·2% per year, p<0.0001), with a non-significant increase in haemorrhagic stroke but reductions of about a fifth in total stroke (2·08% vs 2·54% per year, p=0·002) and in coronary events (4·3% vs 5·3% per year, p<0·0001). In both primary and secondary prevention trials, the proportional reductions in the aggregate of all serious vascular events seemed similar for men and women. In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds. Further trials are in progress." @default.
• W2100089051 created "2016-06-24" @default.
• W2100089051 creator A5006554574 @default.
• W2100089051 creator A5030243760 @default.
• W2100089051 creator A5030250235 @default.
• W2100089051 creator A5033653230 @default.
• W2100089051 creator A5037962146 @default.
• W2100089051 creator A5041941850 @default.
• W2100089051 creator A5042107498 @default.
• W2100089051 creator A5048427107 @default.
• W2100089051 creator A5058165350 @default.
• W2100089051 creator A5065348937 @default.
• W2100089051 creator A5082921958 @default.
• W2100089051 creator A5090621185 @default.
• W2100089051 creator A5090744975 @default.
• W2100089051 date "2009-05-01" @default.
• W2100089051 modified "2023-10-14" @default.
• W2100089051 title "Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials" @default.
• W2100089051 cites W1572054365 @default.
• W2100089051 cites W1735640395 @default.
• W2100089051 cites W1972566357 @default.
• W2100089051 cites W1986003353 @default.
• W2100089051 cites W2024352468 @default.
• W2100089051 cites W2025039880 @default.
• W2100089051 cites W2034942998 @default.
• W2100089051 cites W2044264099 @default.
• W2100089051 cites W2050820265 @default.
• W2100089051 cites W2137408480 @default.
• W2100089051 cites W2137520566 @default.
• W2100089051 cites W2137983259 @default.
• W2100089051 cites W2138597449 @default.
• W2100089051 cites W2142170772 @default.
• W2100089051 cites W2143321563 @default.
• W2100089051 cites W2145496402 @default.
• W2100089051 cites W2156538498 @default.
• W2100089051 cites W2157201048 @default.
• W2100089051 cites W2163207768 @default.
• W2100089051 cites W2164096839 @default.
• W2100089051 cites W2172488527 @default.
• W2100089051 cites W2188507800 @default.
• W2100089051 cites W2247997571 @default.
• W2100089051 cites W2599856343 @default.
• W2100089051 cites W4239471829 @default.
• W2100089051 cites W4245466284 @default.
• W2100089051 doi "https://doi.org/10.1016/s0140-6736(09)60503-1" @default.
• W2100089051 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2715005" @default.
• W2100089051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19482214" @default.
• W2100089051 hasPublicationYear "2009" @default.
• W2100089051 type Work @default.
• W2100089051 sameAs 2100089051 @default.
• W2100089051 citedByCount "3015" @default.
• W2100089051 countsByYear W21000890512012 @default.
• W2100089051 countsByYear W21000890512013 @default.
• W2100089051 countsByYear W21000890512014 @default.
• W2100089051 countsByYear W21000890512015 @default.
• W2100089051 countsByYear W21000890512016 @default.
• W2100089051 countsByYear W21000890512017 @default.
• W2100089051 countsByYear W21000890512018 @default.
• W2100089051 countsByYear W21000890512019 @default.
• W2100089051 countsByYear W21000890512020 @default.
• W2100089051 countsByYear W21000890512021 @default.
• W2100089051 countsByYear W21000890512022 @default.
• W2100089051 countsByYear W21000890512023 @default.
• W2100089051 crossrefType "journal-article" @default.
• W2100089051 hasAuthorship W2100089051A5006554574 @default.
• W2100089051 hasAuthorship W2100089051A5030243760 @default.
• W2100089051 hasAuthorship W2100089051A5030250235 @default.
• W2100089051 hasAuthorship W2100089051A5033653230 @default.
• W2100089051 hasAuthorship W2100089051A5037962146 @default.
• W2100089051 hasAuthorship W2100089051A5041941850 @default.
• W2100089051 hasAuthorship W2100089051A5042107498 @default.
• W2100089051 hasAuthorship W2100089051A5048427107 @default.
• W2100089051 hasAuthorship W2100089051A5058165350 @default.
• W2100089051 hasAuthorship W2100089051A5065348937 @default.
• W2100089051 hasAuthorship W2100089051A5082921958 @default.
• W2100089051 hasAuthorship W2100089051A5090621185 @default.
• W2100089051 hasAuthorship W2100089051A5090744975 @default.
• W2100089051 hasBestOaLocation W21000890511 @default.
• W2100089051 hasConcept C126322002 @default.
• W2100089051 hasConcept C127413603 @default.
• W2100089051 hasConcept C141071460 @default.
• W2100089051 hasConcept C164705383 @default.
• W2100089051 hasConcept C168563851 @default.
• W2100089051 hasConcept C2777466421 @default.
• W2100089051 hasConcept C2777628954 @default.
• W2100089051 hasConcept C2779134260 @default.
• W2100089051 hasConcept C2780645631 @default.
• W2100089051 hasConcept C2993857929 @default.
• W2100089051 hasConcept C44249647 @default.
• W2100089051 hasConcept C500558357 @default.
• W2100089051 hasConcept C71924100 @default.
• W2100089051 hasConcept C78519656 @default.
• W2100089051 hasConcept C82789193 @default.
• W2100089051 hasConceptScore W2100089051C126322002 @default.
• W2100089051 hasConceptScore W2100089051C127413603 @default.
• W2100089051 hasConceptScore W2100089051C141071460 @default.
• W2100089051 hasConceptScore W2100089051C164705383 @default.
• W2100089051 hasConceptScore W2100089051C168563851 @default.

• next